Virginia's Governor Says No — And the Industry Watches What Comes Next

Virginia's Governor Says No — And the Industry Watches What Comes Next

Virginia Governor Abigail Spanberger's decision this week to veto legislation creating the state's first licensed adult-use cannabis retail market is, on one level, a familiar story: a governor and a legislature disagreeing over the details of a cannabis bill. On another level, it crystallizes something much larger — the messy, slow-grinding gap between states where cannabis is technically legal and states where you can actually buy it.

Spanberger vetoed the bill on Wednesday after the General Assembly declined to adopt her proposed amendments at a reconvened session. The governor had sought to delay the retail launch from January 2027 to July 2027, raise the excise tax from 6% to 8%, and reduce per-transaction purchase limits. Lawmakers refused to accept the full package and sent the original bill back to her desk. Her response was a clean veto. Senator Lashrecse Aird summarized the result bluntly: the decision "leaves the commonwealth exactly where we have been since 2021: with an unchecked illicit market." Personal possession and home cultivation have been legal in Virginia for five years. A licensed retail framework has not.

This is the second gubernatorial veto of a retail sales bill in recent Virginia history, and the situation is not simply a matter of a governor being hostile to cannabis. Spanberger has not opposed legalization in principle — her objections have been structural, focused on tax rates and rollout timelines. The challenge for the legislature now is whether it can use the budget process to effectively revive commercial sales, as some lawmakers are already exploring. That route is legally complicated and politically uncertain.

Meanwhile, the week's federal policy signals were clearer — and in at least one case, clarifying. The Department of Transportation issued guidance on May 19 confirming that the April 23 rescheduling of medical cannabis to Schedule III changes nothing for the approximately six million safety-sensitive transportation workers — truck drivers, pilots, train operators, and others — who are still subject to federal drug testing and prohibited from cannabis use. The rescheduling order applied to state-licensed medical cannabis; it did not federally legalize the substance, and it did not alter drug testing protocols. The DOT's guidance exists largely because there was genuine confusion in the workforce after the April announcement. For operators and consumers, the practical message is the same one that legal experts have been delivering since April 23: Schedule III is meaningful, but it is not what anyone initially hoped for.

On the question of what Schedule III does deliver, partners Jonathan Havens and Adam Fayne of law firm Saul Ewing offered one of the week's more useful frameworks, describing the rescheduling as "the most consequential federal change to cannabis law in more than 50 years" — while emphasizing that it is emphatically not federal legalization. The real wins, they argue, are the elimination of the Section 280E tax disallowance (which had pushed effective federal tax rates above 70% for some operators) and the creation of new DEA registration and import-export permitting pathways. The remaining challenges — banking reform, divergent hemp definitions, unresolved FDA-EMA alignment, and the administrative hearing still ahead — are substantial. The DEA's broader rescheduling hearing is set for June 29 in Arlington, Virginia, with May 20 having been the postal deadline for written notices of intent to participate. Expect significant industry representation at that hearing.

California, meanwhile, moved quickly on the registration opportunity. The state's Department of Cannabis Control issued emergency regulations allowing approximately 1,600 dual-licensed retailers and microbusinesses to separate their adult-use and medicinal licences so their medical operations can independently apply for Schedule III DEA registration. The 60-day expedited registration window closes in late June. Operators pursuing this path must maintain physically separate products, distinct inventory records, and separate business accounts — not a trivial operational lift in the compressed timeframe.

On the compassionate access front, both Louisiana and Delaware advanced notable legislation. Louisiana's House passed Senate Bill 270 this week, sending it to the governor's desk; the law would allow terminally ill patients to use medical cannabis while residing in qualifying healthcare facilities from August 1, 2026. Delaware's governor separately signed Ryan's Law this weekend, permitting terminally ill patients to use medical cannabis in hospital settings. These state-level compassionate access measures are modest in scope but meaningful in human terms, and they reflect a broader trend of states extending medical cannabis to the patients who arguably need it most.

Illinois filed a landmark 561-page cannabis omnibus bill this week that would, among other provisions, move intoxicating hemp products out of gas stations and smoke shops and into licensed dispensaries — effectively bringing the hemp THC market under the same regulatory roof as recreational cannabis. Possession limits would double. Vermont's legislature advanced a bill to double possession limits statewide as well.

The throughline across all of this week's policy activity is a widening renegotiation of the terms under which cannabis exists in American public life. States are writing, rewriting, and sometimes refusing to write rules. The federal government has moved in one direction while federal agencies quietly reinforce limits in others. The DEA hearing in June will be one more chapter in a reform process that is neither linear nor inevitable — just relentless.